Jazz Pharmaceuticals plc (JAZZ)

Market Cap	11.75B +37.7%
Revenue (ttm)	4.27B +4.9%
Net Income	-356.15M
EPS	-5.84
Shares Out	61.56M
PE Ratio	n/a
Forward PE	7.79
Dividend	n/a
Ex-Dividend Date	n/a

Volume	799,675
Open	186.94
Previous Close	186.85
Day's Range	185.47 - 191.40
52-Week Range	95.49 - 198.00
Beta	0.23
Analysts	Strong Buy
Price Target	216.92 (+13.61%)
Earnings Date	May 5, 2026

About JAZZ

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 1, 2007
• Employees: 2,890
• Stock Exchange: NASDAQ
• Ticker Symbol: JAZZ
• Website: https://www.jazzpharma.com

Analyst Summary

According to 13 analysts, the average rating for JAZZ stock is "Strong Buy." The 12-month stock price target is $216.92, which is an increase of 13.61% from the latest price.

Price Target

$216.92

(13.61% upside)

Analyst Consensus: Strong Buy